Cantor Fitzgerald’s 4D Molecular Therapeutics FDMT Stock Holding History

Cantor Fitzgerald’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12,500	Closed	-$262K	–	243
2024 Q2	$262K	Buy	+12,500	New	+$314K	0.05%	136

Other funds holding FDMT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cantor Fitzgerald's FDMT Position: Q3 2024 in Review

Cantor Fitzgerald sold out of 4D Molecular Therapeutics (FDMT) in Q3 2024, closing a stake of 12,500 shares — an estimated $262K sold.

Cantor Fitzgerald first reported a position in FDMT in Q2 2024 and held it in 1 quarter. The position peaked at $262K in Q2 2024. 140 funds tracked by Wall St. Rank hold FDMT as of Q3 2024.

Cantor Fitzgerald reported no remaining 4D Molecular Therapeutics position as of Q3 2024 after selling out during the quarter.
Cantor Fitzgerald sold 12,500 4D Molecular Therapeutics shares in Q3 2024, an estimated $262K.
Cantor Fitzgerald first reported a position in 4D Molecular Therapeutics in Q2 2024 and held it in 1 quarter.
Cantor Fitzgerald's 4D Molecular Therapeutics position peaked at $262K in Q2 2024.
140 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2024.

Based on Cantor Fitzgerald's 13F filing for Q3 2024, filed 14 Nov 2024.